System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Epublish

PubMed: 40291446 DOI: 10.1007/s40203-025-00353-1

In silico analysis of Rutin and Morin against diabetes-associated molecular targets.

In Silico Pharmacol 13(2):68

Authors: Rout George Kerry, Soumya Ranjan Mahapatra, Sanghamitra Nayak, Hemangini Naik, Kanika Kisku, Bijayananda Panigrahi, Namrata Misra, Sanatan Majhi

Affiliations

  • Department of Biotechnology, Utkal University, Vani Vihar, Bhubaneswar, Odisha 751004 India.
  • Centre for Biotechnology, Siksha 'O' Anusandhan (Deemed to be University), Kalinga Nagar, Bhubaneswar, Odisha 751003 India.
  • School of Biotechnology, Kalinga Institute of Industrial Technology (KIIT), Deemed to be University, Bhubaneswar, 751024 India.
  • Department of Biotechnology and Bioinformatics, Sambalpur University, Jyoti Vihar, Burla, 768019 India.
  • Department of Botany, Ravenshaw University, Cuttack, 753003 India.
  • Transcription Regulation Group, International Centre for Genetic Engineering and Biotechnology, Delhi, New Delhi 110067 India.
  • KIIT-Technology Business Incubator (KIIT-TBI), Kalinga Institute of Industrial Technology (KIIT), Deemed to be University, Bhubaneswar, 751024 India.

Abstract

Diabetes is one of the oldest diseases known to occur in humans and is regulated by a complex interplay of metabolic, genetic, and environmental factors. Several therapeutic options exist, including medications, exercise, improved health measures, psychological and mental well-being, and amelioration of disparity and depression. Current therapeutic options although are effective, they tends to display side effects that includes significant complications like gastrointestinal discomfort, decreased effectiveness and weight gain. Plant-derived bioactive substances with antidiabetic and/or hypoglycaemic properties have been found to be effective, however, the mechanism of action of the majority of herbs are still being characterized and standardized. However, in the present in-silico prediction for phytocompounds, Rutin (RU) and Morin (MO) revealed them to be more effective than or equal to conventional inhibitors in blocking the enzymes and receptors that contribute to diabetes development. Results of the in-silico investigations have clearly demonstrated the importance of RU and MO in binding diabetic-susceptible enzymes (alpha-amylase, DPP-4, and maltase-glucoamylase) and receptors (GLP-1R, SGLT1 and SGLT2). Additionally, in vitro antidiabetic enzymatic assays demonstrated the possible inhibitory activity of RU and MO against two diabetes-related molecular targets.

MeSH

Diabetes Mellitus, Amylases, Alpha-Glucosidases, Enzymes, Therapeutics, Rutin